KROS
Keros Therapeutics Inc
Price:  
66.31 
USD
Volume:  
345,479.00
United States | Biotechnology
Valuation
Overview
Financials
Forecast
Compare
Historical Price
SolvencyDividends
Transactions
People

KROS WACC - Weighted Average Cost of Capital

The WACC of Keros Therapeutics Inc (KROS) is 7.1%.

The Cost of Equity of Keros Therapeutics Inc (KROS) is 10.45%.
The Cost of Debt of Keros Therapeutics Inc (KROS) is 5.00%.

Range Selected
Cost of equity 7.90% - 13.00% 10.45%
Tax rate 26.20% - 27.00% 26.60%
Cost of debt 5.00% - 5.00% 5.00%
WACC 5.8% - 8.3% 7.1%
WACC

KROS WACC calculation

Category Low High
Long-term bond rate 3.9% 4.4%
Equity market risk premium 4.6% 5.6%
Adjusted beta 0.88 1.46
Additional risk adjustments 0.0% 0.5%
Cost of equity 7.90% 13.00%
Tax rate 26.20% 27.00%
Debt/Equity ratio 1 1
Cost of debt 5.00% 5.00%
After-tax WACC 5.8% 8.3%
Selected WACC 7.1%